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Summary
Background Despite widespread use of intrapartum antibiotic prophylaxis, group B streptococcus remains a leading 
cause of morbidity and mortality in infants in Europe, the Americas, and Australia. However, estimates of disease 
burden in many countries outside of these regions is not available. We aimed to examine the current global burden of 
invasive disease and the serotype distribution of group B streptococcus isolates.
Methods We searched Medline, Embase, and Wholis databases for studies on invasive early-onset (day 0–6) and late-
onset (day 7–89) group B streptococcal disease. Eligible studies were those that described incidence, deaths, or 
serotypes. We also reviewed reference lists and contacted experts to seek unpublished data and data missed by our 
search. Random eﬀ ects meta-analysis was used to pool data. 
Findings 74 studies met the inclusion criteria; 56 studies reported incidence, 29 case fatality, and 19 serotype distribution. 
An additional search for studies that reported serotype distribution from Jan 1, 1980, yielded a total of 38 articles. Only 
ﬁ ve low-income countries were represented in the review and contributed 5% weight to the meta-analysis. 47 (69%) 
studies reported use of any intrapartum antibiotic prophylaxis. Substantial heterogeneity existed between studies. Mean 
incidence of group B streptococcus in infants aged 0–89 days was 0·53 per 1000 livebirths (95% CI 0·44–0·62) and the 
mean case fatality ratio was 9·6% (95% CI 7·5–11·8). Incidence of early-onset group B streptococcus (0·43 per 
1000 livebirths [95% CI 0·37–0·49]) and case fatality (12·1%, [6·2–18·3]) were two-times higher than late-onset disease. 
Serotype III (48·9%) was the most frequently identiﬁ ed serotype in all regions with available data followed by serotypes Ia 
(22·9%), Ib (7·0%), II (6·2%), and V (9·1%). Studies that reported use of any intrapartum antibiotic prophylaxis were 
associated with lower incidence of early-onset group B streptococcus (0·23 per 1000 livebirths [95% CI 0·13–0·59]) than 
studies in which patients did not use prophylaxis (0·75 per 1000 livebirths [0·58–0·89]).
Interpretation More high-quality studies are needed to accurately estimate the global burden of group B streptococcus, 
especially in low-income countries. A conjugate vaccine incorporating ﬁ ve serotypes (Ia, Ib, II, III, V) could prevent 
most global group B streptococcal disease.
Funding Child Epidemiology Reference Group (CHERG), WHO.
Introduction
Group B streptococcus (Streptococcus agalactiae) is the most 
common cause of neonatal sepsis in high-income 
countries.1,2 Disease risk is highest during the ﬁ rst 
3 months of life and declines substantially thereafter. Early-
onset disease (day 0–6) is the result of vertical transmission 
from a colonised mother during or just before delivery.3 
Late-onset disease (day 7–89) can be acquired from the 
mother or from environmental sources.4,5 Case fatality 
from both early-onset and late-onset disease is high, even 
with antibiotic therapy.2,3 Group B streptococcus is also an 
important cause of preterm delivery, antepartum and 
intrapartum stillbirth, and puerperal sepsis.6,7
Prevention of early-onset group B streptococcus has 
become a realistic option, through the use of intrapartum 
antibiotics given to pregnant women with risk factors or 
known carriage of the bacteria (intrapartum antibiotic 
prophylaxis).8–10 This prophylaxis has been implemented 
in most high-income countries since the late 1990s, but 
has been diﬃ  cult to implement in many low-income 
countries and middle-income countries.11–13 Several 
group B strepto coccus vaccines are also at various stages 
of testing and could allow prevention of both early-onset 
disease and late-onset disease.6,14 However, many 
challenges exist to obtaining accurate estimates of 
disease burden, especially for low-income and middle-
income countries, including diﬃ  culties with obtaining 
speci mens and poor laboratory capacity for diagnosis of 
group B streptococcus.
We aimed to estimate the incidence of group B 
streptococcal invasive disease and case fatality in infants 
aged 0–89 days in the era of intrapartum prophylaxis, 
estimate the incidence of early and late onset invasive 
disease, and estimate distribution of group B strepto coccal 
serotypes in invasive disease specimens. Secondary 
objectives were to assess how the incidence of group B 
streptococcus varies with gross national income (GNI) per 
head and geographical region.
Methods
Deﬁ nitions and classiﬁ cation 
We deﬁ ned invasive group B streptococcal disease as 
laboratory isolation of Streptococcus agalactiae from a 
normally sterile site in an infant aged 0–89 days with 
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any signs of clinical disease (eg, sepsis, pneumonia, 
or meningitis). 
Search strategy and selection criteria
We searched Medline, Embase, and Wholis databases 
using the search terms (“Streptococcus agalactiae”[Mesh] 
OR “Streptococcus Group B” OR “Group B Streptococcal”) 
AND Limits: Humans, Publication date 2000/01/01–
2011/09/01. We restricted our search from January 2000, 
to maintain consistency and comparability with other 
publications from WHO Global Burden of Disease and 
the Child Health Epidemiology Reference Group aimed 
at producing disease burden estimates for 2000.15,16 To 
ensure we included all studies in which group B 
streptococcus was not isolated and incidence was zero 
we reviewed all reports that described incidence or 
case fatality from the concurrent neonatal infection 
search in the 2010 global burden of disease project.16 We 
also reviewed reference lists and contacted experts to 
seek unpublished data and data missed by our search. 
No language restrictions were used.
Reports were excluded if they did not describe data 
collected between Jan 1, 2000, and Sept 1, 2011, human 
infants aged 0–89 days at onset of infection episode, 
specimens obtained from a sterile site, laboratory 
investigation for common bacterial pathogens such as 
group B streptococcus, original data (ie, reviews or 
repeated datasets were excluded), denominator data 
(eg, case series were excluded); and data representative of 
the whole population of infants (eg, studies containing 
only information on very high-risk groups [eg, preterm 
infants] were excluded).
Only 19 articles with data on serotypes of group B 
streptococcus fulﬁ lled the inclusion criteria for the 
search from Jan 1, 2000 to Sept 1, 2011, thus an additional 
search for reports with serotype data from Jan 1, 1980, to 
Sept 1, 2011 was done with the same search strategy 
outlined above.
Data extraction 
Two reviewers (CK, KME) examined titles, abstracts, and 
articles independently with identical case deﬁ nitions, 
data abstraction forms, and selection criteria. Dis agree-
ments were resolved by consensus between the two 
reviewers and the lead authors (CK, KME, PTH).
We gathered basic data on author, country and group B 
streptococcal cases, deaths, and serotypes ascertained 
for three age groups: 0–89 days, 0–6 days, and 7–89 days. 
We also gathered data on livebirths in the study 
population. If a study only included inborn babies 
(babies born in the study hospital) then the number of 
livebirths for the whole hospital was used as 
denominator data. If a study included outborn babies 
(babies who were not born in the study hospital but 
born at home or another health facility) then the 
number of livebirths in the whole study population 
(including community births) was used. 
We also gathered data on potential explanatory 
variables (ie, variables that might explain variance in 
incidence or risk of group B streptococcus; table 1). 
First, we obtained data from 2009 World Bank, WHO, 
and Child Health Epidemiology Reference Group data 
sets.15–17 These data were used to categorise countries 
into WHO region (African, southeast Asia, western 
Paciﬁ c, eastern Mediterranean, European, and 
American), gross national income in $US per head 
from 2009 (low income, low-middle income, 
2000–11 (all articles) 1980–2011 
(38 serotype 
articles)
Total 
(68 papers)
Incidence 
(56 papers)
Case 
fatality 
(29 papers)
Serotypes 
(19 papers)
WHO region
Americas 16 (24%) 16 (29%) 9 (31%) 5 (26%) 9 (24%)
Africa 6 (9%) 4 (7%) 3 (10%) 1 (5%) 2 (5%)
Southeast Asia 5 (7%) 5 (9%) 0 0 0
Europe 24 (35%) 20 (36%) 12 (41%) 10 (53%) 19 (50%)
Eastern Mediterranean 4 (6%) 4 (7%) 3 (10%) 0 1 (3%)
Western Paciﬁ c 13 (19%) 7 (13%) 5 (17%) 3 (16%) 7 (18%)
Gross national income (in $US per head)
High income (>12 196) 49 (72%) 41 (73%) 23 (79%) 17 (89%) 33 (87%)
High-middle income (3946–12 195) 5 (7%) 5 (9%) 1 (3%) 2 (11%) 3 (8%)
Low-middle income (996–3945) 9 (13%) 7 (13%) 2 (7%) 0 2 (5%)
Low income (<995) 5 (7%) 3 (5%) 3 (10%) 0 0
Skilled attendance at delivery
≥70% 59 (87%) 49 (88%) 26 (90%) 19 (100%) 37 (97%)
<70% 9 (13%) 7 (13%) 3 (10%) 0 1 (3%)
Study design
Prospective 29 (43%) 27 (48%) 8 (28%) 8 (42%) 14 (37%)
Retrospective 39 (57%) 29 (52%) 21 (72%) 11 (58%) 24 (63%)
Site of delivery
Inborn 62 (91%) 27 (93%) 51 (91%) 19 (100%) 34 (89%)
Outborn 6 (9%) 5 (9%) 2 (7%) 0 4 (11%)
Reporting period  
Complete 44 (65%) 37 (66%) 18 (62%) 17 (89%) 26 (68%)
Incomplete 24 (35%) 19 (34%) 11 (38%) 2 (11%) 12 (32%)
Specimen type 
All sterile sites 54 (79%) 45 (80%) 26 (90%) 17 (58%) 33 (87%)
Blood only 14 (21%) 11 (20%) 3 (10%) 2 (11%) 5 (13%)
Intrapartum antibiotic prophylaxis 
Any intrapartum antibiotic 
prophylaxis used
47 (69%) 43 (77%) 19 (66%) 13 (68%) 17 (45%)
No intrapartum antibiotic 
prophylaxis used
21 (31%) 13 (23%) 10 (34%) 6 (32%) 21 (55%)
Low birthweight* 
<20% 17 (25%) 13 (23%) 10 (34%) 1 (5%) 3 (8%)
20–39% 51 (75%) 43 (77%) 19 (66%) 18 ( 95%) 35 (92%)
≥40% 0 0 0 0 0
*Proportion of infants with group B streptococcus who had low birthweight.
Table 1: Characteristics of included studies
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Year
Europe
Strakova et al21
Andersen et al22
Ekelund et al23
Kuhn et al24
Fluegge et al25
Berardi et al26
Trijbels-Smeulders et al27
van den Hoogen et al28
Hasseltvedt et al29
Hajdu et al30
Neto et al31
Janek et al32
Carbonell-Estrany et al33
Lopez Sastre et al34
Andreu et al35
Persson et al36
Heath et al37
Oddie et al38
Weisner et al39
Vergnano et al40
Subtotal (I2=98·6%, p=0·000)
The Americas
Martin et al41
Vaciloto et al42
Bell et al43
Trotman et al44
Castrodale et al45
Chen et al46
Hyde et al47
Mayor-Lynn et al48
Phares et al49
Puopolo et al50
CDC et al51
Stoll et al52
CDC et al53
Brooks et al54
Cordero et al55
Jordan et al56
Subtotal (I2=97·4%, p=0·000)
Africa
Berkley et al57
Gray et al58
Ojukwu et al59
Cutland et al60
Subtotal (I2=82·9%, p=0·001)
Eastern Mediterranean
Al-Zwaini et al61
Tiskumara et al62
El-Said et al63
Ben Hamida et al64
Subtotal (I2=65·6%, p=0·033)
Western Paciﬁc
Angstetra et al65
Daley et al66
May et al67
Tiskumara et al62
Tiskumara et al62
Kim et al68
Niduvaje et al69
Subtotal (I2=54·7%, p=0·039)
Southeast Asia
Darmstadt et al70
Sundaram et al71
Tiskumara et al62
Tiskumara et al62
Yossuck et al72
Subtotal (I2=0·0%, p=0·612)
Overall (I2=98·3%, p=0·000)
2004
2004
2004
2010
2005
2007
2007
2010
2001
2006
2008
2004
2008
2005
2003
2004
2004
2002
2004
2011
2007
2002
2005
2006
2007
2005
2002
2005
2008
2005
2007
2002
2009
2005
2004
2008
2005
2007
2005
2009
2002
2009
2002
2008
2007
2004
2005
2009
2009
2004
2006
2009
2009
2009
2009
2002
Country
Czech Republic
Denmark
Denmark
France
Germany
Italy
Netherlands
Netherlands
Norway
Norway
Portugal
Slovakia
Spain
Spain
Spain
Sweden
UK
UK
UK
UK
Antigua and Barbuda
Brazil
Jamaica
Jamaica
USA
USA
USA
USA
USA
USA
USA
USA
USA
USA
USA
USA
Kenya
Malawi
Nigeria
South Africa
Iraq
Kuwait
Saudi Arabia
Tunisia
Australia
Australia and New Zealand
Australia and New Zealand
Macau
Malaysia
South Korea
Singapore
Bangladesh
India
India
Thailand
Thailand
Gross national 
income*
High
High
High
High
High
High
High
High
High
High
High
High
High
High
High
High
High
High
High
High
High
Middle
Middle
Middle
High
High
High
High
High
High
High
High
High
High
High
High
Low
Low
Middle
Middle
Middle
High
High
Middle
High
High
High
High
Middle
High
High
Low
Middle
Middle
Middle
Middle
0–89
0–89
0–89
0–6
0–89
0–89
0–89
0–20
0–89
0–89
0–89
0–89
0–6
0–89
0–89
0–89
0–89
0–6
0–89
0–89
0–28
0–2
0–28
0–28
0–6
0–6
0–6
0–6
0–89
0–3
0–6
0–6
0–89
0–89
0–89
7–89
0–59
0–89
0–27
0–27
0–89
0–2
0–28
0–89
0–6
0–2
0–2
0–2
0–2
0–28
0–27
0–28
0–3
0–2
0–2
0–89
Livebirths†
356 250
80 263
64 153
20 131
1 454 520
112 933
608 665
21 429
50 000
28 235
448 531
6538
107 021
164 830
157 848
72 641
794 037
62 786
654 474
130 763
12 000
4746
17 262
32 029
39 628
120 952
248 184
28 659
3 047 059
67 260
1 363 636
6204
2 854 761
427 000
17 926
351 064
27 284
31 458
4135
8129
12 826
44 990
8000
11 201
8303
22 514
30 008
6400
46 140
46 154
4636
10 000
34 362
4689
21 299
11 000
Time period 
(days)‡
Incidence (95% CI)
0·80 (0·71 to 0·90)
0·00 (0·00 to 0·05)
0·34 (0·21 to 0·52)
0·75 (0·42 to 1·23)
0·21 (0·19 to 0·24)
0·50 (0·37 to 0·64)
0·40 (0·36 to 0·46)
0·70 (0·39 to 1·15)
1·18 (0·90 to 1·52)
0·85 (0·54 to 1·26)
0·54 (0·47 to 0·61)
2·60 (1·52 to 4·16)
0·39 (0·28 to 0·53)
0·59 (0·48 to 0·72)
0·26 (0·19 to 0·35)
0·69 (0·51 to 0·91)
0·72 (0·66 to 0·78)
0·57 (0·40 to 0·79)
0·74 (0·68 to 0·81)
0·67 (0·54 to 0·83)
0·57 (0·44 to 0·71)
0·25 (0·05 to 0·73)
0·63 (0·13 to 1·85)
0·87 (0·49 to 1·43)
0·91 (0·61 to 1·30)
0·53 (0·33 to 0·81)
0·96 (0·79 to 1·15)
0·67 (0·57 to 0·78)
2·13 (1·63 to 2·73)
0·74 (0·71 to 0·78)
0·37 (0·24 to 0·55)
0·33 (0·30 to 0·36)
1·45 (0·66 to 2·75)
0·77 (0·74 to 0·81)
0·72 (0·64 to 0·81)
0·33 (0·12 to 0·73)
0·47 (0·40 to 0·55)
0·67 (0·54 to 0·80)
0·95 (0·62 to 1·40)
1·81 (1·37 to 2·35)
0·24 (0·01 to 1·35)
1·97 (1·13 to 3·19)
1·21 (0·50 to 1·91)
0·08 (0·00 to 0·43)
0·31 (0·17 to 0·52)
0·50 (0·14 to 1·28)
0·98 (0·49 to 1·76)
0·35 (0·07 to 0·62)
0·00 (0·00 to 0·44)
0·27 (0·10 to 0·58)
0·03 (0·00 to 0·19)
0·31 (0·04 to 1·13)
0·37 (0·21 to 0·59)
0·13 (0·05 to 0·28)
0·22 (0·01 to 1·20)
0·15 (0·04 to 0·27)
0·10 (0·00 to 0·55)
0·00 (0·00 to 0·11)
0·00 (0·00 to 0·79)
0·14 (0·03 to 0·41)
0·09 (0·00 to 0·51)
0·02 (–0·03 to 0·07)
0·53 (0·44 to 0·62)
–0·5 0 0·5 1·0 1·5 2·0 2·5 3·0
Incidence of group-B-streptococcal disease
Figure 1: Meta-analysis of studies that reported incidence of group B streptococcus in infants with disease onset 0–89 days, 2000–11, by region
*Gross national income in US$ per head. †Number of livebirths in the denominator of the study. ‡Data collection time period in days since the birth of the infant.
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high-middle income, high income), and high versus 
low (≥70% vs <70%) skilled attendance at birth according 
to WHO criteria.15 
We categorised studies as prospective (data gathered 
while the infant was still unwell or in hospital) versus 
retrospective (data gathered after the infant had been 
discharged from hospital). Data on site of delivery were 
also gathered because inborn babies have diﬀ erent risk 
factors for infection than do babies who are outborn. 
Also, delay in specimen collection from outborn babies 
can be longer than in inborn babies. The reporting period 
was categorised as complete versus incomplete. For 
example, we looked for data on early-onset incidence over 
the whole period from day 0–6. If data for this period was 
available it was classiﬁ ed as complete. However, if 
information was only available for day 0–2 then data were 
still recorded but classiﬁ ed as incomplete. Data on 
specimen type were grouped as specimens from all 
sterile sites (blood, cerebrospinal ﬂ uid, bone and joint 
specimens) versus blood only.18,19 Only limited information 
was available for intrapartum antibiotic prophylaxis and 
studies could only be categorised into use of any 
intrapartum antibiotic prophylaxis versus no use of  intra-
partum antibiotic prophylaxis. Infants with low birth- 
weight should comprise 20–30% of all infants with group 
B streptococcus,20 thus we also divided studies into three 
categories of low birthweight: 20% or less, 20–39%, 40% 
or more. 
Group B streptococcal disease is rapidly progressive 
and under-ascertainment can result if specimens are 
not obtained within 24 h of disease onset. Thus, we 
examined articles for indicators such as proportion of 
specimens collected during the ﬁ rst day of illness or on 
the day of birth or careseeking and referral on day one 
of life, but no data were available. Poor laboratory 
techniques can also cause under-ascertainment of 
group B streptococcus, so we also searched for 
information on specimen volume, transport conditions, 
and culture techniques; but data were disparate and 
could not be pooled. We also looked for data on HIV 
status but this was not available in most articles or 
could not be synthesised. 
Year
Europe
Strakova et al21
Fluegge et al25
Berardi et al26
Trijbels-Smeulders et al27
Hasseltvedt et al29
Hajdu et al30
Neto et al31
Carbonell-Estrany et al33
Persson et al36
Heath et al37
Oddie et al38
Weisner et al39
Subtotal (I2=87·8%, p=0·000)
The Americas
Trotman et al44
Castrodale et al45
Hyde et al47
Mayor-Lynn et al48
Phares et al49
Puopolo et al50
Brooks et al54
Cordero et al55
Jordan et al56
Subtotal (I2=86·7%, p=0·000)
Africa
Gray et al58
Milledge et al73
Sigauque et al74
Subtotal (I2=59·9%, p=0·083)
Western Paciﬁc
Matsubara et al75
Park et al96
Cho et al77
Chang et al78
Jiang et al79
Subtotal (I2=0·0%, p=0·836)
Overall (I2=87·3%, p=0·000)
2004
2005
2007
2007
2001
2006
2008
2008
2004
2004
2002
2004
2006
2007
2002
2005
2008
2005
2005
2004
2008
2007
2005
2009
2009
2010
2010
2003
2004
Gross national 
income*
Number of group B 
streptococcus cases
Case fatality ratio
(95% CI)
High
High
High
High
High
High
High
High
High
High
High
High
Middle
High
High
High
High
High
High
High
High
Low
Low
Low
High
High
High
Middle
Middle
0–89
0–89
0–89
0–89
0–89
0–89
0–89
0–3
0–89
0–89
0–7
0–89
0–3
0–6
0–6
0–6
0–89
0–3
0–89
0–89
7–89
0–89
0–3
0–28
0–89
0–89
0–89
0–28
0–28
Country Time period 
(days)
Czech Republic
Germany
Italy
Netherlands
Norway
Norway
Portugal
Spain
Sweden
UK
UK
UK
Jamaica
USA
USA
USA
USA
USA
USA
USA
USA
Malawi
Malawi
Mozambique
Japan
South Korea
South Korea
Taiwan
Taiwan
285
679
56
196
59
24
242
42
52
568
36
486
29
21
166
61
2268
25
146
6
165
57
136
31
6
157
99
19
18
0·01 (0·00–0·03)
0·02 (0·01–0·04)
0·11 (0·04–0·22)
0·11 (0·07–0·16)
0·08 (0·03–0·19)
0·33 (0·16–0·55)
0·07 (0·04–0·11)
0·02 (0·00–0·13)
0·08 (0·02–0·19)
0·09 (0·07–0·12)
0·17 (0·06–0·33)
0·08 (0·06–0·11)
0·07 (0·04–0·10)
0·03 (0·00–0·18)
0·14 (0·03–0·36)
0·04 (0·01–0·08)
0·07 (0·02–0·16)
0·06 (0·05–0·07)
0·16 (0·05–0·36)
0·14 (0·09–0·20)
0·17 (0·00–0·64)
0·32 (0·25–0·40)
0·11 (0·06–0·16)
0·33 (0·21–0·47)
0·21 (0·14–0·28)
0·13 (0·04–0·30)
0·22 (0·12–0·32)
0·17 (0·00–0·64)
0·10 (0·06–0·16)
0·08 (0·04–0·15)
0·05 (0·00–0·26)
0·17 (0·04–0·41)
0·09 (0·06–0·13)
0·10 (0·07–0·12)
Group-B-streptococcal death ratio
0–0·1 0·1 0·2 0·3 0·4 0·5
Figure 2: Meta-analysis of studies that reported data for case fatalilty caused by group B streptococcus in infants with disease onset 0–89 days, 2000–11, by region 
*Gross national income in US$ per head. †Data collection time period in days since the birth of the infant.
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Statistical analyses 
We used random-eﬀ ects meta-analysis to calculate 
weighted mean estimates across studies and 95% CIs for 
incidence of group B streptococcus, case fatality, and 
serotype distribution. Random-eﬀ ects logistic regression 
was used to investigate the eﬀ ect of gross national 
income, WHO region, and other explanatory variables 
for group B streptococcus estimates while taking account 
of within-study and within-country correlations. We 
decided a priori that all eﬀ ect measures should be 
adjusted for study design, delivery site, reporting period, 
specimen type, intrapartum antibiotic use, and proportion 
of low birthweight infants in the ﬁ nal model. However, 
we judged that gross national income, WHO region, and 
skilled attendance would be highly correlated and only 
gross national income should be included in the ﬁ nal 
model. Crude and adjusted odds ratios and their 95% CIs 
were calculated. Statistical analyses were done with 
STATA (version 11).
Role of the funding source
The sponsor of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
the data in the study and had ﬁ nal responsibility for the 
decision to submit for publication. 
Results
2709 papers were identiﬁ ed from the Medline and Wholis 
search from Jan 1, 2000, to Sept 1, 2011, and 423 titles 
were retained. No additional articles were obtained from 
the Embase search, 111 titles were obtained from the 
concurrent WHO Global Burden of Disease neonatal-
infection search, and 114 titles were obtained from experts 
in neonatal care and reference lists. No unpublished data 
that met our inclusion criteria were identiﬁ ed. 74 papers 
were retained after the abstracts were reviewed and our 
inclusion criteria were applied (webappendix pp 1–11). 
56 studies reported incidence data,21–72 29 report ed 
case fatality data,21,25–27,29–31,33,36–39,44,45,47–50,54–56,58,73–79 and 19 report-
ed serotype data (webappendix pp 1–11). The serotype 
search from 1980–2011 yielded a total of 38 papers 
(webappendix pp 1–11).
Overall, 8718 infants were positive for group B 
streptococcus in 36 countries (median number of 
infants per study 21·5 [IQR 3·5–92·5]; table 1). 47 (69%) 
studies reported use of intrapartum antibiotic 
prophylaxis (web appendix p 12). This proportion was 
higher in Europe (22 [92%] of 24) and the Americas (13 
[81%] of 16) than in the eastern Mediterranean (one 
[25%] of four) and Africa (one [17%] of six). No studies 
in low-income countries reported use of intrapartum 
antibiotic prophylaxis.
To assess whether any publication bias was likely in 
our study we did scatter plots of incidence and 
case fatality rate against sample size and SE to determine 
whether any correlation existed. These analyses yielded 
non-signiﬁ cant results both for data on incidence 
(p=0·223) and case fatality (p=0·206).
56 papers reported incidence data for the overall period 
0–89 days (table 1). Studies from low-income countries 
carried only 5% weight in the meta-analysis. Mean 
incidence was 0·53 per 1000 livebirths (95% CI 0·44–0·62; 
ﬁ gure 1). Incidence was highest in Africa followed by the 
Americas  and Europe. Southeast Asia had the lowest 
incidence. The studies were very heterogeneous in both 
the overall analysis and within regions (p<0·0001), except 
for southeast Asia (p=0·612). Even within countries a 
great deal of heterogeneity existed. 
42 studies reported incidence data for early-onset 
(0–6 days) group B streptococcus; 31 (74%) had data for 
the complete period (0–6 days) and 34 (81%) reported use 
of intrapartum antibiotic prophylaxis. Only three low-
income countries (Kenya, Malawi, Bangladesh) had data 
for early-onset group B streptococcus. The mean 
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incidence of early-onset disease was 0·43 (95% CI 
0·37–0·49). Incidence was highest in studies from Africa 
(0·53, 95% CI 0·15–0·92]) followed by the Americas 
(0·50, 0·43–0·57) and Europe (0·45, 0·34–0·56). Studies 
from southeast Asia reported the lowest incidence (0·11, 
95% CI 0·012–0·220). 
18 papers reported any data for incidence of late-onset 
(7–89 days) group B streptococcus. The average 
incidence of late-onset disease was 0·24 (95% CI 
0·17–0·30). Incidence was again highest in Africa (0·71, 
95% CI 0·38–1·04) followed by the Americas (0·31, 
0·16–0·89).
29 papers reported data for case fatality in infants aged 
0–89 days; 484 deaths occurred in 6135 infants positive for 
group B streptococcus (table 1). The mean case fatality ratio 
was 9·6% (95% CI 7·5–11·8; ﬁ gure 2). Early-onset 
case fatality (12·1%, 95% CI 6·2–18·3) was twice as high as 
late-onset death (6·8%, 4·3–9·4). The case fatality ratio was 
three times higher in low-income countries (12·6%, 95% CI 
10·8–14·9) than in high-income countries (4·6%, 2·1–9·1).
Studies Participants Subgroup 
estimates; incidence 
(95% CI)
Univariable 
regression; odds ratio 
(95% CI)*
Multivariable regression; 
adjusted odds ratio*† 
(95% CI) 
Live births Group B 
streptococcus
WHO region p=0·035
Americas 16 8 638 370 5849 0·67 (0·54–0·80) 1 ··
Africa 7 71 006 100 1·21 (0·50–1·91) 1·85 (0·77–4·45) ··
Southeast Asia 5 81 350 5 0·016 (0·033–0·065) 0·087 (0·025–0·30) ··
Europe 20 5 396 048 2701 0·57 ( 0·448–0·71) 0·86 (0·45–1·63) ··
Eastern Mediterranean 4 77 017 30 0·35 (0·073–0·62) 0·60 (0·24–1·52) ··
Western Paciﬁ c 4 164 155 33 0·15 (0·042–0·27) 0·26 (0·11–0·62) ··
Gross national income ($US per head) p=0·691 p=0·710
High income (≥12 196) 41 14 151 386 8537 0·56 (0·47–0·65) 1 1
High-middle income (3946–12 195) 5 108 306 80 0·83 (0·42–1·23) 1·92 (0·76– 4·89) 1·759 (0·68–4·57)
Low-middle income (996–3945) 7 99 512 17 0·17 (0·013–0·33) 0·33 (0·12–0·89) 0·190 (0·066–0·54)
Low income (<995) 3 68 742 84 0·94 (0·040–1·91) 1·77 (0·59–5·31) 1·802 (0·60–5·42)
Skilled attendance at delivery p=0·236
≥70% 49 14 304 018 8630 0·65 (0·11–1·19) 1 ··
<70% 7 123 928 88 0·56 (0·47–0·64) 0·66 (0·25–1·76) ··
Study design p=0·906 p=0·902
Prospective 27 6 529 308 3793 0·47 (0·34–0·60) 1 1
Retrospective 29 7 898 638 4925 0·65 (0·54–0·75) 1·03 (0·66–1·59) 0·975 (0·66–1·44)
Delivery site p=0·682 p=0·130
Inborn 51 14 223 575 8625 0·57 (0·49–0·66) 1 1
Outborn 5 204 371 93 0·40 (0·14–0·65) 0·81 (0·30–2·20) 0·50 (0·20–1·23)
Reporting period p=0·219 p=0·026
Complete 37 14 016 126 8556 0·64 (0·55–0·74) 1 1
Incomplete 19 411 820 162 0·35 (0·23–0·46) 0·71 (0·41–1·23) 0·54 (0·32–0·93)
Specimen type p=0·608 p=0·901
All sterile sites 45 13 999 368 8430 0·557 (0·47–0·65) 1 1
Blood only 11 428 578 288 0·60 (0·34–0·86) 1·15 (0·68–1·92) 1·03 (0·62–1·71)
Intrapartum antibiotic prophylaxis p=0·968 p=0·112
Any intrapartum antibiotic 
prophylaxis used
43 13 831 239 8279 0·55 (0·46–0·64) 1 1
No intrapartum antibiotic 
prophylaxis used
13 596 707 439 0·64 (0·37–0·90) 1·02 (0·50–2·08) 1·81 (0·85–3·85)
Low birthweight* p=0·014 p=0·005
20–39% 43 12 893 707 7859 0·69 (0·60–0·78) 1 1
<20% 13 1 534 239 859 0·38 (0·28– 0·57) 0·57 (0·36–0·89) 0·51 (0·32–0·81)
Data are number or incidence (95% CI), odds ratio (95% CI), or adjusted odds ratio (95% CI). *Proportion of infants with group B streptococcus who were low 
birthweight. †Adjusted for gross national income, design, delivery site, reporting period, specimen type, use of intrapartum antibiotic prophylaxis, and proportion of 
infants with low birthweight.
Table 2: Regression analyses of the eﬀ ect of explanatory variables on incidence of group B streptococcus in infants with disease onset 0–89 days, 2000–11
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38 serotype studies published from Jan 1, 1980 to June 1, 
2011, fulﬁ lled the inclusion criteria (table 1, ﬁ gure 3). 
Serotype III accounted for almost half of all isolates 
followed by serotypes Ia, Ib, II, and V; a small proportion 
of serotypes were non-typeable (ﬁ gure 3). 
No serotype studies from southeast Asia were identiﬁ ed, 
and only one study from the eastern Mediterranean region 
(Morocco) and two studies from Africa (Nigeria and South 
Africa) were recorded. Distribution of group B streptococcus 
serotypes seemed to be similar across WHO regions 
(ﬁ gure 3). Five serotypes (Ia, Ib, II, III, V) accounted for 
more than 85% of serotypes in all regions with serotype 
data (Africa 98% [112], Americas 96% [2152], Europe 93% 
[2295], western Paciﬁ c 89% [569], eastern Mediterranean 
88% [51]). 
33 serotype studies were from high-income countries. 
Five studies from middle-income countries (South Africa, 
Nigeria, Morocco, Romania, and Argentina) reported 
serotypes; 94 (43%) of 221 cases in middle-income countries 
were serotype III. However, no serotype studies from low-
income countries were identiﬁ ed.
We also examined serotype distribution by disease 
onset (ﬁ gure 3). 221 (37%) of 604 early-onset serotypes 
were type III by contrast with 347 (53%) of 653 late-onset 
serotypes. 242 (40%) early-onset serotypes were type I 
compared with 196 (30%) of late-onset serotypes. By 
contrast, serotype distribution did not seem to change 
substantially over the three decades of data collection. 
Serotype III accounted for 48% (1324) of isolates in the 
1980s, 49% (822) of isolates in the 1990s, and 50% (544) 
of the isolates from 2000–10. Serotype V accounted for 
9% (245) of isolates in the 1980s, 9% (143) of isolates in 
the 1990s, and 10% (112) of the isolates from 2000–10.
The only explanatory variables that seemed to be 
strongly predictive of group B streptococcus risk were the 
proportion of infants positive for group B streptococcus 
who had low birthweight and reporting period (table 2). 
Studies with less than 20% of infants with low birth 
weight reported lower odds of group B streptococcal 
infection than did studies with proportions ranging from 
20–39%. Studies with incomplete reporting recorded 
lower odds of group B streptococcal  infection than did 
studies with complete reporting.
Infants in countries with low gross national income 
had higher odds of group B streptococcal infection than 
did those in countries with high gross national income, 
but this result was not signiﬁ cant  (table 2). No association 
was reported between incidence of group B streptococcus 
and gross national income (adjusted odds ratio 0·99, 
95% CI 0·97–1·01, p=0·071). Incidence of group B 
streptococcus in infants aged 0–89 days was higher in 
studies that reported no use of intrapartum antibiotic 
prophylaxis than in infants in studies that reported any 
intrapartum antibiotic prophylaxis, but this eﬀ ect was 
not signiﬁ cant (table 2).
We also constructed a multivariable model to closely 
investigate the eﬀ ect of WHO region. In this analysis 
only the Asian region had a signiﬁ cantly diﬀ erent risk of 
group B streptococcus than the baseline group (Americas; 
adjusted odds ratio 0·077, 95% CI 0·023–0·260) after 
adjusting for all variables in the initial model except for 
gross national income.
We also repeated the analyses, assessing the eﬀ ect of all 
explanatory variables on early-onset incidence of group B 
streptococcus. The only variable with an important associ-
ation with risk of early-onset disease was use of intrapartum 
antibiotic prophylaxis. No use of prophylaxis was associ-
ated with a 2·2 times increased odds of early-onset group 
B streptococcal infection (odds ratio 2·20, 95% CI 
1·59–3·40; incidence of early-onset disease 0·23 per 
1000 livebirths in studies with any intrapartum antibiotic 
prophylaxis com pared with 0·75 per 1000 livebirths in 
studies with no intrapartum antibiotic prophylaxis). 
Discussion
More studies are needed to accurately estimate the global 
burden of group B streptococcus, especially in low-income 
countries. We judge our overall estimate of group B 
streptococcus incidence (0·53 per 1000 livebirths) to be an 
underestimate of the global incidence. Incidence and 
case fatality were two-times higher in infants who had 
group B streptococcal disease in the ﬁ rst week of life 
(0–6 days) compared with later infancy (7–89 days). The 
disease is often rapidly fulminating and many cases can be 
missed because of diﬃ  culties with obtaining specimens 
before babies die. This issue is especially important in 
African and Asian countries with high case-fatality rates 
due to group B streptococcus. Our estimate also mirrors 
the current use of intrapartum antibiotic prophylaxis in 
high-income countries as it was used in almost 70% of the 
studies. This intervention has high eﬃ  cacy in preventing 
early-onset group B streptococcus and has substantially 
reduced the incidence of early-onset disease since its 
introduction in the 1990s.8,9,37
Risk of group B streptococcal disease was two-times 
less in studies with small proportions (<20%) of infected 
low-birthweight infants than in studies with proportions 
ranging from 20–39%. Infants with low birthweight have 
a high risk of group B streptococcal infection and under-
representation in a study sample can lead to substantial 
underestimations.37 Studies done in the UK and USA 
report an eight-times greater risk of group B streptococcal 
infection in infants under 1·5 kg and up to three-times 
greater risk in infants 1·4–2·5 kg than babies with 
normal birthweight.37,47
Studies done in Africa reported the highest incidence 
of group B streptococcal disease; almost three-times 
higher than in the Americas. By contrast, studies done in 
southeast Asia reported the lowest risk and two studies 
in this region reported no group B streptococcus. The 
disparities between Africa and Asia are striking. The low 
incidence in Asia could be a true regional estimate or 
could be due to high previous antibiotic use, high 
case fatality before specimen collection, or study design 
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issues including small sample sizes and incomplete 
periods for data collection.
Distribution of group B streptococcus serotypes was 
strikingly similar across the WHO regions and no 
evidence was shown that distribution had changed over 
the past 30 years. Serotype III accounted for almost half 
of all the isolates followed by serotype Ia, II, and V. Five 
studies from middle-income countries (South Africa, 
Nigeria, Morocco, Romania, and Argentina) reported on 
distribution of serotypes. However, no studies in southeast 
Asia and in low-income countries were identiﬁ ed and 
serotypes might be diﬀ erent in these countries.
Our review had some limitations. Infants born to 
HIV-positive mothers have a high risk of late-onset 
group B streptococcal disease,80 but we were unable to 
assess the eﬀ ect of HIV status in our meta-analysis due 
to insuﬃ  cient data. We also were only able to include 
ﬁ ve studies from low-income countries and ﬁ ve studies 
from Asia and calculation of representative estimates of 
global or regional incidence of group B streptococcus 
were not possible. We also had few indicators of study 
quality. We were not able to obtain data on the 
proportion of specimens taken within 24 h of disease 
onset and had no clear measures of laboratory accuracy 
and reliability.
We also did not provide estimates of group B strepto-
coccal cases and deaths by WHO region because we 
judged the studies to be too heterogeneous. This 
heterogeneity was due to the wide range of data sources 
retained, especially in the studies from low-income 
countries. However, we did adjust our regression analyses 
for important explanatory variables and presented both 
unadjusted and adjusted eﬀ ect measures. Also, an 
important strength of our study was our comprehensive 
search strategy. We included all papers from the 
concurrent global burden of disease neonatal infection 
study regardless of whether group B streptococcus was 
isolated or not. Our study also seems to be the ﬁ rst 
synthesis of global group B streptococcus incidence, 
case fatality, and serotype data. Previous Cochrane 
reviews have only assessed the eﬀ ect of important 
preventive interventions such as intrapartum antibiotic 
prophyl axis81,82 and vaginal chlorhexidine.83
We included both inborn and outborn babies but all 
studies had to include contact with a hospital that could 
undertake laboratory investigations for common bacterial 
pathogens such as group B streptococcus. These studies 
are biased towards patients with severe disease,84,85 and 
more babies with group B streptococcal infection could 
have been included in these studies than those in the 
total population, thereby inﬂ ating our incidence estimate. 
Families who attend hospitals also have better access to 
health care and higher socioeconomic status than do 
those who do not attend hospitals.86 However, we showed 
that studies with lowest levels of skilled attendance at 
delivery (<70%) and lowest gross national income 
reported the highest risk of group B streptococcal 
infection. This ﬁ nding contrasts with other studies that 
suggest that mothers with the highest socioeconomic 
status have the highest risk of infection.87,88
This study has important implications for research and 
policy development. Low-income countries had the 
highest risk of group B streptococcus disease and 
mortality, yet little incidence and serotype data were 
available from these countries. High-quality group B 
streptococcus data are urgently needed from low-income 
countries, especially from Asia. These data are required 
to formulate prevention policies including the optimum 
use of intrapartum antibiotic prophylaxis and the 
potential use of group B streptococcus vaccines. 
A simple risk-based algorithm for use of intrapartum 
antibiotic prophylaxis in preterm deliveries, premature 
rupture of membranes, and maternal pyrexia could be 
applied in health facilities in low-income countries. 
However, because of logistical issues, very few low-
income countries are implementing any intrapartum 
antibiotic policies despite their known eﬃ  cacy; and even 
when policies are implemented, they are often limited. 
Intrapartum antibiotic prophylaxis also is not currently 
reaching the women most in need—those with high-risk 
home deliveries.8,89 Emphasis must be placed on 
improving use of intrapartum antibiotic prophylaxis in 
low-income settings.
Our data also indicate that a conjugate vaccine 
incorporating ﬁ ve serotypes (Ia, Ib, II, III, V) could 
prevent over 85% of global group B streptococcal disease 
in infants aged younger than 3 months. Serotype 
distribution seems to be similar in Africa, western Paciﬁ c, 
Europe, the Americas, and the eastern Mediterranean 
regions and has not changed over the past 30 years. This 
ﬁ nding contrasts with the regional variation in serotype 
distribution seen with other vaccine preventable 
diseases.90,91 Group B streptococcus conjugate vaccines 
are at advanced stages of testing and phase 3 trials will 
soon begin in Africa.14,92 Vaccination of pregnant women 
also has the potential to reduce premature births, 
stillbirths, and puerperal sepsis caused by group B 
streptococcus.6
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